Today (17 January 2017) we have launched a new series of research podcasts that aim to shine a light on research at the Trust.
The first in the series features Dr Toby Maher talking about recently-published research into idiopathic pulmonary fibrosis (IPF), a condition where there is progressive scarring of the lungs. This limits the amount of oxygen that gets into a patient’s blood, causing breathlessness from everyday activities like walking.
In this episode, we explore recent research into home monitoring for IPF and how this is might help with research trials in the future for example by providing a method for testing how efficient current and new treatments are.
Listen to episode one: Idiopathic pulmonary fibrosis; the future of home monitoring in research
Dr Maher is the lead consultant for clinical trials in the interstitial lung disease unit at the Trust and runs an active clinical and translational research programme. His research interests include:
- basic and translational research into idiopathic pulmonary fibrosis with a major focus on biomarker discover
- early phase clinical trials
- the pre-clinical validation of putative targets and compound for the treatment of fibrosing lung disease.
He is currently UK principal investigator for a number of commercial studies of novel compounds being tested in trials for IPF and other interstitial lung diseases.